Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Condition: HER2-Positive Early Stage Breast Cancer
MeSH terms: Breast Neoplasms
Intervention: Paclitaxel; Trastuzumab; Lapatinib; Pegfilgrastim
Intervention description: The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.; Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
Intervention MeSH terms: Paclitaxel; Trastuzumab; Lapatinib
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 20.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Paclitaxel; Trastuzumab; Lapatinib; HER2; 13-002

Summary:

      The purpose of this study is to study a new treatment for HER2-positive breast cancer.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically confirmed adenocarcinoma with HER2/neu
             immunohistochemistry 3+ or FISH-amplified breast cancer with a ratio of ≥ 2.0

          -  Tumor size of ≤ 3 cm and node-negative disease. Nodes with single cells or tumor
             clusters < 0.2 mm by H&E or IHC are considered node-negative. Patients with
             micrometastasis (nodes with tumor clusters between 0.02 and 0.2 cm) are allowed.
             Further axillary dissection will be determined by the patient's surgeon as per
             standard of care.

          -  Patients must be ≥18 years of age.

          -  Patients must have an ECOG performance status of 0 or 1.

          -  Treatment should be started within 90 days of the final surgical procedure for breast
             cancer.

          -  Patients may have bilateral synchronous breast tumors. Patients may have received
             hormonal therapy for the purpose of chemoprevention but must be willing to discontinue
             prior to enrollment and while participating in this trial.

          -  If patients have peripheral neuropathy, it must be ≤ grade 1.

          -  Patients must be willing to discontinue sex hormonal therapy e.g., birth control
             pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of
             childbearing potential must be willing to consent to using effective contraception
             while on treatment and for a reasonable period thereafter.

          -  Hematologic parameters: absolute neutrophil count (ANC) ≥1500/μL and platelet count
             ≥100,000/μL.

          -  Non-hematologic parameters: total bilirubin must be ≤ 1.5 X institutional upper limit
             of normal (ULN), transaminases (SGOT or SGPT) ≤ 3.0 x ULN.

          -  Negative HCG pregnancy test for premenopausal women of reproductive capacity and for
             women less than 12 months after the menopause. LVEF by ECHO (with strain if possible)
             with LVEF of ≥ 50%. If an ECHO cannot be done, a MUGA may be performed.

          -  Patients must give written, informed consent indicating their understanding of and
             willingness to participate in the study.

        Exclusion Criteria:

          -  Patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy,
             immunotherapy, or biotherapy for current breast cancer.

          -  Pregnant or breastfeeding patients.

          -  Patients with a concurrently active second malignancy, other than adequately treated
             non-melanoma skin cancers or in situ cervical cancer.

          -  Patients with unstable angina, congestive heart failure, or with a history of a
             myocardial infarction within 12 months. Patients with high-risk uncontrolled
             arrhythmias (ventricular tachycardia, high-grade AV block, supraventricular
             arrhythmias which are not adequately rate-controlled). Patients are excluded if they
             have grade 3 QT prolongation (Appendix F) (>500 ms) or require drugs that may prolong
             the QT.

          -  Subjects who have current active hepatic (including hepatitis B or C) or biliary
             disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones).

          -  Patients with active, unresolved infections.

          -  Patients with a sensitivity to E. coli derived proteins.